Intelligence coverage: 60%

Basic profile, financials, and market data are shown below. Deep research is building in the background.

CTSO

Cytosorbents Corp

Healthcare · Surgical & Medical Instruments & Apparatus

$4.30Sep 24, 2026

AI confidence 60% · prior close shown (market closed)

Investment Snapshot

Weak evidence · 1 source

Why it matters

Cytosorbents Corp shows stable business momentum based on AlphaOS pipeline evidence.

Why it matters: Revenue +0% YoY in Q2 FY2026.

TrajectoryStable

3 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

  • Revenue +0% YoY in Q2 FY2026

Pipeline evidence · 0d ago

CTSO's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on CTSO.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q2 2026

Full CTSO earnings analysis

Reported figures for Cytosorbents Corp — research only, not investment advice.

Revenue YoY
+0.1%
EPS YoY
-333.3%

Latest Intelligence

Updated

What happened recently for Cytosorbents Corp (CTSO) — events, not interpretation.

Event
Reported Q2 2026 revenue +0% YoY.
Also
Last session September 24, 2026 at $4.3.
Source
Q2 2026 earnings

Research & analysis only — not investment advice.

Building company intelligence…

Cytosorbents Corp (CTSO)

Healthcare · Surgical & Medical Instruments & Apparatus

Investment Snapshot above is the primary AlphaOS analysis for Cytosorbents Corp — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:
Healthcare
Market cap:
$270.22M
Revenue:
$9.63M

CTSO earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow Cytosorbents Corp through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Connected companies and research pages from the AlphaOS knowledge graph.